|
Left Ventricular Hypertrophy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, vasodilators and diuretics, which stimulate adrenoceptor activity and increase angiotensin II levels, were found to be less effective in reversing LV hypertrophy.
|
1380616 |
1992 |
|
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
ACE is responsible for the generation of angiotensin II, which is implicated in the development of left ventricular hypertrophy, an independent risk factor for morbidity and mortality in hypertension.
|
7820539 |
1994 |
|
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme and angiotensinogen genes in patterns of left ventricular hypertrophy and in diastolic dysfunction.
|
8582095 |
1996 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Exciting new discoveries concerned with polymorphisms of genes coding for angiotensin converting enzyme (ACE) and angiotensinogen suggest that Ang II may be genetically associated with increased risk for myocardial infarction, hypertension and left ventricular hypertrophy.
|
8583476 |
1995 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
1.The relationship between the angiotensinogen (AGT) T174M, angiotensin converting enzyme (ACE) insertion/deletion (I/D) and the angiotensin II type 1 receptor (AT1) genetic markers and left ventricular hypertrophy was examined in normal subjects and those with aortic stenosis.2.
|
8800593 |
1996 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Low predictability of ACE genotype markers for LVH together with conflicting reports on the influence of RAS genetic variants on angiotensin II production suggests that the simple RAS paradigm may not apply for hypertension.
|
9433518 |
1997 |
|
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
We studied the role of 3 potential modifier genes, i.e., angiotensinogen (AGT), angiotensin II receptor 1a (AT1a), and endothelin-1 (END1) on the phenotypic expression of LVH in patients with hypertrophic cardiomyopathy (HCM).
|
9444881 |
1997 |
|
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The development of left ventricular hypertrophy (LVH) in subjects with hypertrophic cardiomyopathy (HCM) is variable, suggesting a role for modifying factors such as angiotensin II.
|
9822439 |
1998 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Angiotensinogen gene M235T polymorphism predicts left ventricular hypertrophy in endurance athletes.
|
10440164 |
1999 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Frequency of IT genotype of ATG gene in patients with LVH was significantly (P<0.01) greater than that in normal controls or marginally (P=0.1) higher than that in patients without LVH.
|
10646957 |
2000 |
|
Left Ventricular Hypertrophy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
The potential role of nitric oxide in the hypertrophic growth of the left ventricle.
|
10805403 |
2000 |
|
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
CTD_human |
The potential role of nitric oxide in the hypertrophic growth of the left ventricle.
|
10805403 |
2000 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Untreated transgenic rats overexpressing the human renin and angiotensinogen genes (dTGR) feature hypertension and severe left ventricular hypertrophy with focal areas of necrosis, and die at age 7 weeks.
|
10880382 |
2000 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Five genetic polymorphisms of the RAAS (ACE, AGTR1, AGT, CMA, CYP11B2) were analyzed in all patients and the results of genetic analysis were correlated to severity of AS and LVH to determine the importance of the polymorphisms for LVH.
|
11275936 |
2001 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, neither ID ACE-gene polymorphism nor ATI-receptor gene and angiotensinogen gene polymorphism was associated with LVH.
|
11688760 |
2001 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggest an association of combined angiotensin I-converting enzyme gene I/D polymorphism genotypes, and angiotensinogen gene M235T polymorphism genotypes with left ventricular hypertrophy due to long-term athletic training.
|
11737220 |
2001 |
|
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The development of left ventricular hypertrophy in subjects with hypertrophic cardiomyopathy (HCM) is variable, suggesting a role for modifying factors such as angiotensin II.
|
11751703 |
2001 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The angiotensinogen T174M and M235T and the AT1-receptor A1166C polymorphisms were related to the change in LVH during antihypertensive treatment with an AT1-receptor antagonist; of these angiotensinogen T174M was the most powerful.
|
11910301 |
2002 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with mild-to-moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind study to receive treatment with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan (n = 43), or the beta1-adrenergic receptor blocker atenolol (n = 43).
|
12022239 |
2002 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We determined the B2BKR genotype of 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, included in a double-blind study to receive treatment for 48 weeks with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol.
|
12640257 |
2003 |
|
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphism of the AGT M235T gene but not ACE I/D gene is associated with greater LVMi and relative wall thickness, indicating more concentric LVH, in Chinese peritoneal dialysis patients.
|
12675870 |
2003 |
|
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The angiotensin II subtype 1 (AT1) receptor antagonist valsartan suppressed the elevated blood pressure completely and left ventricular hypertrophy incompletely, but did not affect the other phenotypes.
|
14620933 |
2003 |
|
Left Ventricular Hypertrophy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Cardiac hypertrophy in aryl hydrocarbon receptor null mice is correlated with elevated angiotensin II, endothelin-1, and mean arterial blood pressure.
|
14644620 |
2003 |
|
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
CTD_human |
Cardiac hypertrophy in aryl hydrocarbon receptor null mice is correlated with elevated angiotensin II, endothelin-1, and mean arterial blood pressure.
|
14644620 |
2003 |
|
Left Ventricular Hypertrophy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Adrenomedullin modulates hemodynamic and cardiac effects of angiotensin II in conscious rats.
|
14751847 |
2004 |